Dr. Suzanne M. Cole
Claim this profileUT Southwestern/Simmons Cancer Center-Dallas
Expert in Skin Cancer
Studies Bladder Cancer
16 reported clinical trials
38 drugs studied
Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage II
Stage I
2Bladder Cancer
Stage IV
Stage II
Stage I
Affiliated Hospitals
UT Southwestern/Simmons Cancer Center-Dallas
UT Southwestern Clinical Center At Richardson/Plano
Clinical Trials Suzanne M. Cole is currently running
Radium-223 + Cabozantinib
for Kidney Cancer with Bone Metastasis
This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.
Recruiting1 award Phase 216 criteria
Eribulin + Chemotherapy
for Bladder Cancer
This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
More about Suzanne M. Cole
Clinical Trial Related4 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Suzanne M. Cole has experience with
- Atezolizumab
- Nivolumab
- Avelumab
- Gemcitabine Hydrochloride
- Ipilimumab
- Cabozantinib S-malate
Breakdown of trials Suzanne M. Cole has run
Skin Cancer
Bladder Cancer
Transitional Cell Carcinoma
Kidney Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Suzanne M. Cole specialize in?
Suzanne M. Cole focuses on Skin Cancer and Bladder Cancer. In particular, much of their work with Skin Cancer has involved Stage IV patients, or patients who are Stage II.
Is Suzanne M. Cole currently recruiting for clinical trials?
Yes, Suzanne M. Cole is currently recruiting for 9 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Suzanne M. Cole has studied deeply?
Yes, Suzanne M. Cole has studied treatments such as Atezolizumab, Nivolumab, Avelumab.
What is the best way to schedule an appointment with Suzanne M. Cole?
Apply for one of the trials that Suzanne M. Cole is conducting.
What is the office address of Suzanne M. Cole?
The office of Suzanne M. Cole is located at: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas 75390 United States. This is the address for their practice at the UT Southwestern/Simmons Cancer Center-Dallas.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.